Skip to main content
Erschienen in: European Radiology 2/2020

25.10.2019 | Gastrointestinal

Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors

verfasst von: Tyler J. Fraum, Roberto Cannella, Daniel R. Ludwig, Richard Tsai, Muhammad Naeem, Maverick LeBlanc, Amber Salter, Allan Tsung, Anup S. Shetty, Amir A. Borhani, Alessandro Furlan, Kathryn J. Fowler

Erschienen in: European Radiology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine whether the LI-RADS imaging features of primary liver carcinomas (PLCs) other than hepatocellular carcinoma (non-HCC PLCs) differ between patients considered high risk (RF+) versus not high risk (RF−) for HCC and to compare rates of miscategorization as probable or definite HCC between the RF+ and RF− populations.

Methods

This retrospective study included all pathology-proven non-HCC PLCs imaged with liver-protocol CT or MRI from 2007 to 2017 at two liver transplant centers. Patients were defined per LI-RADS v2018 criteria as RF+ or RF−. Two independent, blinded readers (R1, R2) categorized 265 lesions using LI-RADS v2018. Logistic regression was utilized to assess for differences in imaging feature frequencies between RF+ and RF− patients. Fisher’s exact test was used to assess for differences in miscategorization rates.

Results

Non-HCC PLCs were significantly more likely to exhibit nonrim arterial phase hyperenhancement (R1: OR = 2.94; R2: OR = 7.09) and nonperipheral “washout” (R1: OR = 3.65; R2: OR = 7.69) but significantly less likely to exhibit peripheral “washout” (R1: OR = 0.30; R2: OR = 0.10) and delayed central enhancement (R1: OR = 0.18; R2: OR = 0.25) in RF+ patients relative to RF− patients. Consequently, non-HCC PLCs were more often miscategorized as probable or definite HCC in RF+ versus RF− patients (R1: 23.3% vs. 3.6%, p < 0.001; R2: 11.0% vs. 2.6%, p = 0.009).

Conclusions

Non-HCC PLCs are more likely to mimic HCCs on CT and MRI in the LI-RADS target population than in patients without LI-RADS-defined HCC risk factors.

Key Points

The presence of LI-RADS-defined risk factors for HCC tends to alter the imaging appearances of non-HCC PLCs, resulting in higher frequencies of major features and lower frequencies of LR-M features.
Non-HCC PLCs are more likely to be miscategorized as probable or definite HCC in the LI-RADS target population than in patients without LI-RADS-defined HCC risk factors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830CrossRef Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830CrossRef
2.
Zurück zum Zitat Brunt E, Aishima S, Clavien PA et al (2018) cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology 68:113–126CrossRef Brunt E, Aishima S, Clavien PA et al (2018) cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology 68:113–126CrossRef
3.
Zurück zum Zitat Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADSM(LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRef Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADSM(LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRef
4.
Zurück zum Zitat Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB (2018) Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY) 43:13–25CrossRef Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB (2018) Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY) 43:13–25CrossRef
5.
Zurück zum Zitat Xu J, Igarashi S, Sasaki M et al (2012) Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int 32:1156–1164CrossRef Xu J, Igarashi S, Sasaki M et al (2012) Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int 32:1156–1164CrossRef
6.
Zurück zum Zitat Brunt EM, Paradis V, Sempoux C, Theise ND (2015) Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. Hepatic Oncol 2:255–273CrossRef Brunt EM, Paradis V, Sempoux C, Theise ND (2015) Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. Hepatic Oncol 2:255–273CrossRef
7.
Zurück zum Zitat Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325CrossRef Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325CrossRef
8.
Zurück zum Zitat Fraum TJ, Fowler KJ, Rohe E et al (2017) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the Liver Imaging Reporting and Data System version 2014. Radiology 286:158–172CrossRef Fraum TJ, Fowler KJ, Rohe E et al (2017) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the Liver Imaging Reporting and Data System version 2014. Radiology 286:158–172CrossRef
9.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef
10.
Zurück zum Zitat Corwin MT, Fananapazir G, Jin M, Lamba R, Bashir MR (2016) Differences in Liver Imaging and Reporting Data System categorization between MRI and CT. AJR Am J Roentgenol 206:307–312CrossRef Corwin MT, Fananapazir G, Jin M, Lamba R, Bashir MR (2016) Differences in Liver Imaging and Reporting Data System categorization between MRI and CT. AJR Am J Roentgenol 206:307–312CrossRef
11.
Zurück zum Zitat Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9:811–818CrossRef Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9:811–818CrossRef
12.
Zurück zum Zitat Choi SH, Lee SS, Park SH et al (2019) LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 290:388–397CrossRef Choi SH, Lee SS, Park SH et al (2019) LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 290:388–397CrossRef
13.
Zurück zum Zitat Sorensen HT, Friis S, Olsen JH et al (1998) Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28:921–925CrossRef Sorensen HT, Friis S, Olsen JH et al (1998) Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28:921–925CrossRef
14.
Zurück zum Zitat Tang A, Bashir MR, Corwin MT et al (2017) Evidence supporting LI-RADS major features for CT- andMR imaging–based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 286:170554 Tang A, Bashir MR, Corwin MT et al (2017) Evidence supporting LI-RADS major features for CT- andMR imaging–based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 286:170554
15.
Zurück zum Zitat Potretzke TA, Tan BR, Doyle MB et al (2016) Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 207:25–31CrossRef Potretzke TA, Tan BR, Doyle MB et al (2016) Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 207:25–31CrossRef
16.
Zurück zum Zitat Fowler KJ, Sheybani A, Parker RA 3rd et al (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201:332–339CrossRef Fowler KJ, Sheybani A, Parker RA 3rd et al (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201:332–339CrossRef
17.
Zurück zum Zitat Lee HS, Kim MJ, An C (2019) How to utilize LR-Mfeatures of the LI-RADS to improve the diagnosis of combined hepatocellularcholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 29:2408–2416CrossRef Lee HS, Kim MJ, An C (2019) How to utilize LR-Mfeatures of the LI-RADS to improve the diagnosis of combined hepatocellularcholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 29:2408–2416CrossRef
18.
Zurück zum Zitat Aoki K, Takayasu K, Kawano T et al (1993) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings. Hepatology 18:1090–1095CrossRef Aoki K, Takayasu K, Kawano T et al (1993) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings. Hepatology 18:1090–1095CrossRef
19.
Zurück zum Zitat de Campos RO, Semelka RC, Azevedo RMet al (2012) Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging 36:1139–1147 de Campos RO, Semelka RC, Azevedo RMet al (2012) Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging 36:1139–1147
20.
Zurück zum Zitat Ebied O, Federle MP, Blachar A et al (2003) Hepatocellular-cholangiocarcinoma:helical computed tomography findings in 30 patients. J Comput Assist Tomogr 27:117–124CrossRef Ebied O, Federle MP, Blachar A et al (2003) Hepatocellular-cholangiocarcinoma:helical computed tomography findings in 30 patients. J Comput Assist Tomogr 27:117–124CrossRef
21.
Zurück zum Zitat Jarnagin WR, Weber S, Tickoo SK et al (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94:2040–2046CrossRef Jarnagin WR, Weber S, Tickoo SK et al (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94:2040–2046CrossRef
22.
Zurück zum Zitat Nishie A, Yoshimitsu K, Asayama Y et al (2005) Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR Am J Roentgenol 184:1157–1162CrossRef Nishie A, Yoshimitsu K, Asayama Y et al (2005) Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR Am J Roentgenol 184:1157–1162CrossRef
23.
Zurück zum Zitat Sanada Y, Shiozaki S, Aoki H et al (2005) A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma. Assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 32:185–195CrossRef Sanada Y, Shiozaki S, Aoki H et al (2005) A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma. Assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 32:185–195CrossRef
24.
Zurück zum Zitat Wells ML, Venkatesh SK, Chandan VS et al (2015) Biphenotypic hepatic tumors: imaging findings and review of literature. Abdom Imaging 40:2293–2305CrossRef Wells ML, Venkatesh SK, Chandan VS et al (2015) Biphenotypic hepatic tumors: imaging findings and review of literature. Abdom Imaging 40:2293–2305CrossRef
25.
Zurück zum Zitat Park SH, Lee SS, Yu E et al (2017) Combined hepatocellular-cholangiocarcinoma:gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 46:267–280CrossRef Park SH, Lee SS, Yu E et al (2017) Combined hepatocellular-cholangiocarcinoma:gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 46:267–280CrossRef
26.
Zurück zum Zitat Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382CrossRef Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382CrossRef
27.
Zurück zum Zitat Sheng RF, Xie YH, Ji Y et al (2016) MR comparative study of combined hepatocellular-cholangiocarcinoma in normal, fibrotic, and cirrhotic livers. Abdom Radiol (NY) 41:2102–2114CrossRef Sheng RF, Xie YH, Ji Y et al (2016) MR comparative study of combined hepatocellular-cholangiocarcinoma in normal, fibrotic, and cirrhotic livers. Abdom Radiol (NY) 41:2102–2114CrossRef
28.
Zurück zum Zitat Gülberg V, Haag K, Rössle M, Gerbes AL (2002) Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 35:630–634CrossRef Gülberg V, Haag K, Rössle M, Gerbes AL (2002) Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 35:630–634CrossRef
29.
Zurück zum Zitat IavaroneM PF, Vavassori S et al (2013) Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol 58:1188–1193CrossRef IavaroneM PF, Vavassori S et al (2013) Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol 58:1188–1193CrossRef
30.
Zurück zum Zitat Kang Y, Lee JM, Kim SH et al (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid–enhanced MR images. Radiology 264:751–760CrossRef Kang Y, Lee JM, Kim SH et al (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid–enhanced MR images. Radiology 264:751–760CrossRef
31.
Zurück zum Zitat Rimola J, Forner A, Reig M et al (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798CrossRef Rimola J, Forner A, Reig M et al (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798CrossRef
32.
Zurück zum Zitat Péporté AR, Sommer WH, Nikolaou K et al (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPAenhanced MRI. Eur J Radiol 82:e101–e106CrossRef Péporté AR, Sommer WH, Nikolaou K et al (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPAenhanced MRI. Eur J Radiol 82:e101–e106CrossRef
33.
Zurück zum Zitat Sammon J, Fischer S, Menezes R et al (2018) MRI features of combined hepatocellular- cholangiocarcinoma versusmass forming intrahepatic cholangiocarcinoma. Cancer Imaging 18:8CrossRef Sammon J, Fischer S, Menezes R et al (2018) MRI features of combined hepatocellular- cholangiocarcinoma versusmass forming intrahepatic cholangiocarcinoma. Cancer Imaging 18:8CrossRef
34.
Zurück zum Zitat Choi SY, Kim YK, Min JH et al (2018) Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acidenhanced MR imaging. Eur Radiol 28:1–12CrossRef Choi SY, Kim YK, Min JH et al (2018) Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acidenhanced MR imaging. Eur Radiol 28:1–12CrossRef
35.
Zurück zum Zitat Wengert GJ, Baltzer PAT, Bickel H et al (2017) Differentiation of intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma in the cirrhotic liver using contrast-enhanced MR imaging. Acad Radiol 24:1491–1500CrossRef Wengert GJ, Baltzer PAT, Bickel H et al (2017) Differentiation of intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma in the cirrhotic liver using contrast-enhanced MR imaging. Acad Radiol 24:1491–1500CrossRef
36.
Zurück zum Zitat Choi SH, Lee SS, Kim SY et al (2017) Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid–enhanced MR imaging and dynamic CT. Radiology 282:771–781CrossRef Choi SH, Lee SS, Kim SY et al (2017) Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid–enhanced MR imaging and dynamic CT. Radiology 282:771–781CrossRef
38.
Zurück zum Zitat Davenport MS, Khalatbari S, Liu PS et al (2014) Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 272:132–142CrossRef Davenport MS, Khalatbari S, Liu PS et al (2014) Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 272:132–142CrossRef
39.
Zurück zum Zitat Kierans AS, Makkar J, Guniganti P et al (2019) Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 49:e205–e215CrossRef Kierans AS, Makkar J, Guniganti P et al (2019) Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 49:e205–e215CrossRef
40.
Zurück zum Zitat Zen C, Zen Y, Mitry RR et al (2011) Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 17:943–954CrossRef Zen C, Zen Y, Mitry RR et al (2011) Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 17:943–954CrossRef
Metadaten
Titel
Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors
verfasst von
Tyler J. Fraum
Roberto Cannella
Daniel R. Ludwig
Richard Tsai
Muhammad Naeem
Maverick LeBlanc
Amber Salter
Allan Tsung
Anup S. Shetty
Amir A. Borhani
Alessandro Furlan
Kathryn J. Fowler
Publikationsdatum
25.10.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 2/2020
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-019-06448-6

Weitere Artikel der Ausgabe 2/2020

European Radiology 2/2020 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.